Genmab A/S (GMAB)
34.15
+1.50
(+4.59%)
USD |
NASDAQ |
Sep 15, 16:00
34.15
0.00 (0.00%)
After-Hours: 20:00
Genmab Enterprise Value : 24.16B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 24.16B |
| September 14, 2026 | 23.26B |
| September 11, 2026 | 23.16B |
| September 10, 2026 | 23.01B |
| September 09, 2026 | 23.50B |
| September 08, 2026 | 23.79B |
| September 04, 2026 | 23.83B |
| September 03, 2026 | 24.31B |
| September 02, 2026 | 24.20B |
| September 01, 2026 | 23.64B |
| August 31, 2026 | 23.57B |
| August 28, 2026 | 23.61B |
| August 27, 2026 | 24.13B |
| August 26, 2026 | 23.92B |
| August 25, 2026 | 24.28B |
| August 24, 2026 | 23.48B |
| August 21, 2026 | 23.74B |
| August 20, 2026 | 23.72B |
| August 19, 2026 | 24.13B |
| August 18, 2026 | 23.45B |
| August 17, 2026 | 23.38B |
| August 14, 2026 | 22.84B |
| August 13, 2026 | 22.48B |
| August 12, 2026 | 22.53B |
| August 11, 2026 | 22.19B |
| Date | Value |
|---|---|
| August 10, 2026 | 22.20B |
| August 07, 2026 | 22.43B |
| August 06, 2026 | 21.58B |
| August 05, 2026 | 21.24B |
| August 04, 2026 | 21.10B |
| August 03, 2026 | 20.89B |
| July 31, 2026 | 21.01B |
| July 30, 2026 | 20.87B |
| July 29, 2026 | 20.80B |
| July 28, 2026 | 21.08B |
| July 27, 2026 | 20.96B |
| July 24, 2026 | 21.01B |
| July 23, 2026 | 21.18B |
| July 22, 2026 | 20.99B |
| July 21, 2026 | 20.70B |
| July 20, 2026 | 20.43B |
| July 17, 2026 | 20.92B |
| July 16, 2026 | 21.07B |
| July 15, 2026 | 21.13B |
| July 14, 2026 | 20.92B |
| July 13, 2026 | 20.96B |
| July 10, 2026 | 21.08B |
| July 09, 2026 | 21.55B |
| July 08, 2026 | 21.41B |
| July 07, 2026 | 21.19B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 529.11B |
| Ascendis Pharma A/S | 15.33B |
| Zealand Pharma A/S | 853.67M |
| Bavarian Nordic A/S | 2.039B |
| Evaxion AS | 18.46M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 302.57M |
| Revenue (Quarterly) | 1.153B |
| Total Expenses (Quarterly) | 850.79M |
| EPS Diluted (Quarterly) | 0.4903 |
| Gross Profit Margin (Quarterly) | 92.73% |
| Profit Margin (Quarterly) | 26.23% |
| Earnings Yield | 3.70% |
| Operating Earnings Yield | 6.12% |
| Normalized Earnings Yield | 4.512 |